In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Director, Liver Institute Northwest
Seattle, WA
Dr. Kowdley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: 89Bio, CymaBay Therapeutics, Genfit, Gilead, GlaxoSmithKline, Hanmi, HighTide, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, Pliant, and Viking
Receives Royalities: UpToDate
Consulting fees: 89Bio, AbbVie, Calliditas Therapeutics, CymaBay Therapeutics, Gilead, Genfit, Gilead, Inipharm, Intercept, Madrigal, Mirum, NGM, and Pliant
Faculty:
Marlyn Mayo, MD
Professor of Internal Medicine
UT Southwestern Medical Center
Dallas, TX
Dr. Mayo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: CymaBay Therapeutics, Genfit, GlaxoSmithKline, Intercept, Intra-Sana Laboratories, Ipsen, Mallinckrodt, Mirum, Target RWE
Consulting Fees: CymaBay Therapeutics, GlaxoSmithKline, Ipsen, Mallinckrodt
Atoosa Rabiee, MD
Chief of Transplant Services
Washington DC VA Medical Center
Washington, DC
No relevant financial relationships to report.
Reviewers/Content Planners/Authors:
- Jennifer Brutsche has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- John Maeglin has nothing to disclose.
- Tim Person has nothing to disclose.
- Katie Sheridan has nothing to disclose.
- Mara Siegel has nothing to disclose.
- Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.